CARDIAC amyloidosisEARLY diagnosisCARDIAC magnetic resonance imagingThis article provides information on the diagnosis and management of cardiac amyloidosis (CA), a condition characterized by abnormal protein deposits in the heart tissue. CA can be caused by two main types of amyloidosis: light ...
Evaluation and Management of the Cardiac Amyloidosis[J] . Joseph B. Selvanayagam,Philip N. Hawkins,Biju Paul,Saul G. Myerson,Stefan Neubauer.Journal of the American College of Cardiology . 2007 (22)Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of ...
Emerging Advances in the Management of Cardiac Amyloidosis Amyloidosis is a disease in which proteins misfold, aggregate into fibrils, and deposit extracellularly disrupting organ architecture and function. There a... MN Vranian,BW Sperry,J Valent,... - 《Current Cardiology Reports》 被引量: 5...
Evaluation and Management of the Cardiac Amyloidosis [Erratum to document cited in CA148:253001].Evaluation and Management of the Cardiac Amyloidosis [Erratum to document cited in CA148:253001].Selvanayagam, Joseph BHawkins, Philip NPaul, BijuMyerson...
Management of cardiac amyloidosis initially is to treat the underlying heart failure. Pacemaker implantation is usually required in patients with any conduction abnormalities. Transplantation is the next step with worsening heart failure. However, the aim of any treatment in amyloidosis, irrespective of ...
Cardiac amyloidosis is a form of infiltrative cardiomyopathy typically presenting with progressive heart failure. The clinical presentation and morphological findings often overlap with other cardiovascular diseases, and frequently results in misdiagnosis and consequent under-reporting. Cardiovascular imaging is pl...
1,4,76,78 Position statements on the evaluation and management of patients with cardiac amyloidosis do not address women-specific experiences or treatments, likely due to a lack of available evidence.79 Specific recommendations and guidelines around heart failure specific to women in Canada are ...
Typical HFpEF must be distinguished from other causes of the clinical syndrome of heart failure, which are treated differently. Diagnosis is challenging and requires the demonstration of objective evidence of congestion or poor cardiac output using assessment of clinical history, physical examination, natr...
In patients with HCM and > 1 red flag for the diagnosis of cardiac amyloidosis, serum and urine immunofixation and/or serum free light chain titration in combination with radionuclide bone scintigraphy with technetium-labelled bisphosphonates are recommended. CMR with non-contrast T1 mapping and extra...
of HF due to primary valvular disease (see ACC/AHA guidelines on management of patients with valvular heart disease) (8)or congenital malformations, and we have not included recommendations for the treatment of specific myocardial disorders (e.g., hemochromatosis, sarcoidosis, or amyloidosis). ...